Proteomics international Laboratories Ltd (PIQ.ASX).
Biotechnology: Diagnostics
About PIQ
Proteomics International Laboratories Ltd (PIQ.ASX) is a revenue generating medical technology company at the forefront of precision medicine and predictive diagnostics. In conjunction with Sonic Healthcare USA, PIQ is currently rolling out its world-first, predictive diagnostic test, PromarkerD, which can predict the onset of diabetic kidney disease (DKD) before clinical symptoms appear, up to four years in advance.
Proteomics International has several diagnostics in its pipeline, namely a world first blood test for Endometriosis (affects 1 in 9 women), and Oesophageal Cancer (1 in 20 cancer deaths). These diagnostics are in the final stages of validation and if successful present blockbuster opportunties.
Candour and PIQ
In a previous role Dirk and Alastair assisted PIQ’s IPO. We subsequently followed the Company closely and were formally engaged in 2018.
We have played a critical role in the transformation of PIQ, focusing the company’s messaging, successfully executing three capital raises, at successively higher prices, introducing supportive brokers & institutions (national & international) to the register.
These initiatives have resulted in a supportive shareholder base that has re-rated the company 4-6x. We continue to provide advice, preparing the company for key commercialisation milestones.
Candour Commentary
Recent Announcement Example
1 / Item Title
1 / Item Title